A Look At Penumbra (PEN) Valuation As Trial Hopes Meet A High Earnings Multiple

Penumbra stock at a glance

Penumbra (PEN) is drawing investor attention after recent trading left the stock around US$321, with returns roughly flat over the past month and lower over the past 3 months despite a stronger 1 year performance.

See our latest analysis for Penumbra.

At around US$321, Penumbra’s recent share price pullback over the past quarter contrasts with a stronger 1 year total shareholder return of 25.55%. This suggests earlier momentum has cooled as investors reassess growth prospects and risks.

If Penumbra’s move has you looking at other health focused opportunities tied to technology, this could be a good moment to scan 39 healthcare AI stocks

With Penumbra’s shares roughly flat in the short term but showing a stronger 1-year return, the key question is whether recent prices leave room for upside or if the stock already reflects future growth.

Most Popular Narrative: 12% Undervalued

Penumbra’s most followed narrative puts fair value around $363, above the last close at $321.06, framing the current price as a discount to that outlook.

The soon to be released STORM PE randomized trial is poised to provide Level 1 evidence comparing Penumbra's thrombectomy technology to standard anticoagulation for pulmonary embolism, a positive outcome could expand guideline adoption, significantly accelerate procedure volumes, and drive substantial revenue growth by rapidly increasing penetration in a very underpenetrated, large market.

Read the complete narrative.

Want to see what underpins that fair value gap? The narrative leans heavily on faster earnings growth, firmer margins, and a rich future profit multiple. Curious which assumptions really move the needle here and how they tie into that 7% discount rate and long term revenue targets? The full story joins those pieces together with far more detail.

Result: Fair Value of $363.36 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on trial and product execution, with any disappointing STORM PE data or slower than expected uptake in key thrombectomy lines potentially undermining that valuation story.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: High Multiple Signals Caution

Analysts see Penumbra as around 12% undervalued versus their US$363.36 fair value, but the current P/E of 73.8x tells a tougher story. That is far above the US Medical Equipment industry at 25.2x, the peer average at 26.2x, and the fair ratio of 28.1x.

In plain terms, the stock trades at a rich premium that leaves less room for disappointment if growth, margins, or trial outcomes fall short. With such a gap between today’s P/E and the fair ratio the market could move toward, how comfortable are you with that valuation risk?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mixed signals on price and valuation can look confusing at first, so it makes sense to check the details yourself and decide where you stand. If you want a quick way to see what is driving optimism around the stock, start with 2 key rewards

Looking for more investment ideas?

If Penumbra has sharpened your thinking, do not stop here. Broadening your watchlist now could help you spot opportunities before momentum builds elsewhere.

• Target potential mispricings by scanning companies that combine quality with value through the 46 high quality undervalued stocks
• Prioritize resilience by focusing on businesses screened for strong finances and robust fundamentals using the solid balance sheet and fundamentals stocks screener (46 results)
• Get ahead of the crowd by checking a screener containing 21 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com